UNSPSC 51171649: Lactitol dihydrate

This classification denotes an artificial sweetener with the molecular formula C12H24O11.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1F5S85F60B, chemically known as d-glucitol, 4-o-.beta.-d-galactopyranosyl-, dihydrate, but more generally known as lactitol dihydrate, which bears US NIH Compound Identifier 157354. European Medicines Agency schedules lactitol dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08385MIG.

Most nations, for tariff purposes, schedule lactitol dihydrate under HS 29400000. SMILES: C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O.O.O.

UNSPSC 51171649 Lactitol dihydrate is a Commodity code that nominally names a specific pharmaceutical ingredient, but recent state and local opportunities tagged with this code show little activity directly aligned with procurement of that substance. The three recent opportunities span offender drug testing services, a pharmacy benefit management information-gathering initiative, and multi-state cooperative purchasing for generic pharmaceuticals and OTC products — none of which centers on lactitol dihydrate as a line item. The code shows fragmented issuing-body activity across county corrections departments, state health and human services commissions, and multi-state cooperative purchasing alliances, with no clear pattern of repeat buyers or concentrated demand under this specific commodity designation.

Geographic activity appears across Texas (Collin County and Texas HHS Commission) and Minnesota (MMCAP, administered through the Minnesota Department of Administration), with participation extending to Oregon through the cooperative purchasing vehicle. The most recent concrete opportunity is Collin County Community Supervision and Corrections Department RFP 2026-327 for offender specimen collection and drug testing services, posted July 9, 2026, with proposals due July 23, 2026 at 2:00 p.m., estimated contract value $600,000 over two years with three optional one-year renewals — though this solicitation emphasizes testing services and lab screening rather than procurement of lactitol dihydrate itself. The Texas HHS Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs but did not advance to formal solicitation at the time the source was compiled. MMCAP's generic pharmaceuticals RFP (due March 26, 2026) focused on multi-source products through authorized wholesalers but did not specify lactitol dihydrate as a required commodity. The code's recent posting activity suggests it may be misaligned with the actual goods or services being procured, or the commodity itself sees limited direct procurement through formal state and local channels.